

Information for Patients on Osteonecrosis of the Jaw

Among statements prepared for patients and their healthcare professionals by various independent organizations about osteonecrosis of the jaw (ONJ) is the statement from the National Osteoporosis Foundation (NOF; see next page). Although Merck & Co., Inc., does not necessarily endorse the perspectives or opinions expressed within the statements of these various organizations, you may find the NOF statement to be a helpful start of a discussion with your healthcare professionals. If you have questions about ONJ, talk with your healthcare professionals. The Prescribing Information for oral and intravenous (IV) bisphosphonates contains information about ONJ. Additional information or resources about ONJ are listed below about ONJ; these can also be accessed at merck.com.

Prescribing Information for Oral Bisphosphonates

<http://www.fosamax.com/fosamax/shared/documents/english/pi.pdf>
http://www.fosamax.com/fosamax/shared/documents/english/pi_plus_d.pdf
<http://www.actonel.com/global/prescribingInfo-040506.pdf>
<http://www.actonel.com/global/prescribingInfo-AwC-040506.pdf>
<http://www.rocheusa.com/products/Boniva/PI.pdf>
<http://www.pgpharma.com/pi/US-Didronel.pdf>
<http://www.products.sanofi-aventis.us/skelid/skelid.html>

Prescribing Information for IV Bisphosphonates

http://www.rocheusa.com/products/Boniva/Injection_PI.pdf
<http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf>
<http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf>